Our primary outcome was the presence and number of presenting symptoms (Table 1) from illness onset until study enrollment. Symptom groups included gastrointestinal, hydration, lower respiratory, musculoskeletal, neurological, rash or oral changes, systemic, and upper respiratory. Anosmia or ageusia, cough, conjunctivitis, and fever were analyzed independently without being grouped with other symptoms. Secondary outcomes included (1) presence of core COVID-19 symptoms (≥1 of ageusia, anosmia, cough, or fever)19 (link); (2) chest radiography performance and treatment provided; and (3) hospitalization, intensive care unit (ICU) admission, and revisits to any ED or to any health care provider (including the ED) within 14 days of the index ED visit.
Sumner M.W., Xie J., Zemek R., Winston K., Freire G., Burstein B., Kam A., Emsley J., Gravel J., Porter R., Sabhaney V., Mater A., Salvadori M.I., Berthelot S., Beer D., Poonai N., Moffatt A., Wright B, & Freedman S.B. (2023). Comparison of Symptoms Associated With SARS-CoV-2 Variants Among Children in Canada. JAMA Network Open, 6(3), e232328.
Corresponding Organization : University of Calgary
Other organizations :
Western University, Children's Hospital of Eastern Ontario, University of Ottawa, University of Toronto, Hospital for Sick Children, SickKids Foundation, Montreal Children's Hospital, McGill University, McGill University Health Centre, McMaster Children's Hospital, Queen Elizabeth II Health Sciences Centre, Dalhousie University, Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal, Janeway Children's Health and Rehabilitation Centre, British Columbia Children's Hospital, University of British Columbia, University of Saskatchewan, Public Health Agency of Canada, Children's Hospital Research Institute of Manitoba, Children's Hospital of Winnipeg, University of Manitoba, London Health Sciences Centre, Queen's University, Kingston Health Sciences Centre, Stollery Children's Hospital, University of Alberta, Research Canada
Presence and number of presenting symptoms (gastrointestinal, hydration, lower respiratory, musculoskeletal, neurological, rash or oral changes, systemic, and upper respiratory, as well as anosmia or ageusia, cough, conjunctivitis, and fever)
Presence of core COVID-19 symptoms (≥1 of ageusia, anosmia, cough, or fever)
Chest radiography performance and treatment provided
Hospitalization, intensive care unit (ICU) admission, and revisits to any ED or to any health care provider (including the ED) within 14 days of the index ED visit
control variables
None explicitly mentioned
Annotations
Based on most similar protocols
Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to
get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
